Medical devices · head to head

DXCM vs PODD

DEXCOM INC and INSULET CORP, side by side on the measures that account for debt and cash — each built from filed accounts.

01

Side by side

The two diverge most on net debt / ebitda: −2.3× for DXCM against 0.7× for PODD. Whether that gap is justified is a judgement this page does not make.

DEXCOM INC compared with INSULET CORP
MeasureDXCMPODDSector median
EV / EBITDA*26.0×18.0×17.0×
EV / Sales*6.5×3.7×3.9×
Net debt / EBITDA−2.3×0.7×1.6×
Return on capital34.7%20.0%19.2%
Operating margin19.6%17.5%18.8%
Free cash flow margin23.1%13.9%14.6%

Green marks the reading conventionally read as cheaper or stronger on that row — a direction, not a recommendation, and the two companies frequently win different rows. * Price-based multiples are a snapshot taken 2026-09-09; the rest come from filed accounts. A dash means the measure could not be computed — each company page says why.

02

The full picture

This page compares two companies on ratios. Neither ratio table shows what it would cost to buy either business, how that cost is built, or which filing each term came from — those are on the company pages.